Developing Novel Drug Candidates

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Our goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

We are listed on the AIM market of the London Stock Exchange (symbol ‘SUMM’) and the NASDAQ Global Market (symbol ‘SMMT’).  Further information is available in our dedicated Investor Relations section.

Calendar

2016 Scrip Awards

Quintiles’ Clinical Advance of the Year Award

Summit Therapeutics’ Phase 2 CoDIFy study of ridinilazole in Clostridium difficile infection

Stocks

Share Price

LSE: SUMM
202.50p 0.00
at 04:26pm GMT 24 Mar 2017

NASDAQ: SMMT
$12.53 -0.11
at 03:59pm ET 24 Mar 2017